Patents Examined by Marianne M. Cintins
  • Use of NK.sub.1 receptor antagonists for preparing cardio-regulatory drugs
    Patent number: 5852044
    Abstract: The invention relates to the use of NK.sub.1 receptor antagonists for the preparation of drugs with a cardioregulatory action, intended in particular for controlling heart rate disorders and cardiac dysrhythtmia.
    Type: Grant
    Filed: April 21, 1997
    Date of Patent: December 22, 1998
    Assignee: Sanofi
    Inventors: Christiane Gueudet, Vincent Santucci, Philippe Soubrie
  • Quinoxaline derivatives useful in therapy
    Patent number: 5852016
    Abstract: Compounds of formula (I), wherein A represents N or CH; R.sup.1 and R.sup.2 independently represent C.sup.1-4 alkyl, halo or CF.sub.3 ; R.sup.3 represents C.sub.1-4 alkyl (optionally substituted), C.sub.3-7 cycloalkyl, CF.sub.3 or aryl; R.sup.4 represents H, C.sub.3-7 cycloalkyl or C.sub.1-6 alkyl (optionally substituted); and their pharmaceutically acceptable derivatives; are useful in the treatment of, inter alia, neurodogenerative disorders.
    Type: Grant
    Filed: March 21, 1997
    Date of Patent: December 22, 1998
    Assignee: Pfizer Inc.
    Inventors: Michael Jonathan Fray, Charles Eric Mowbray, Alan Stobie
  • Process for the treatment or prevention of herpes
    Patent number: 5849786
    Abstract: The present invention related to the use of at least one active ingredient of the flavonoid family in the preparation of compositions for the treatment and/or prevention of herpes.
    Type: Grant
    Filed: April 24, 1996
    Date of Patent: December 15, 1998
    Inventors: Christian-Georges Bidel, Jean Poirson
  • Peripherally acting anti-pruritic opiates
    Patent number: 5849762
    Abstract: Anti-pruritic compositions and methods of using the compositions for the prevention or treatment of pruritus comprising: ##STR1## wherein M is ##STR2## wherein: R, R.sup.2, R.sup.3, R.sup.4, R.sup.7, Ar.sup.1 and Ar.sup.2 are as defined in the specification in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: July 14, 1997
    Date of Patent: December 15, 1998
    Assignee: Adolor Corporation
    Inventors: John J. Farrar, Alan Cowan
  • Carbonate compounds, non-aqueous electrolytic solutions and batteries comprising non-aqueous electrolytic solutions
    Patent number: 5847188
    Abstract: A novel carbonate compound represented by the general formula ?I!:R.sup.1 CH.sub.2 O--CO--OCH.sub.2 R.sup.2 ?I!wherein R.sup.1 represents a hydrogen atom, an alkyl group or an alkyl group substituted with one or more halogen atoms, and R.sup.2 represent an alkyl group having no hydrogen atom at the .alpha.-position thereof or an alkyl group substituted with one or more halogen atoms having no hydrogen atom at the .alpha.-position thereof, with the proviso that R.sup.1 is not identical to R.sup.2, which has excellent properties as solvent, is disclosed. A non-aqueous electrolytic solution and a battery utilizing the novel carbonate compound are also disclosed.
    Type: Grant
    Filed: April 17, 1997
    Date of Patent: December 8, 1998
    Assignee: Mitsui Chemicals, Inc.
    Inventors: Keiichi Yokoyama, Akio Hiwara, Shigeru Fujita, Atsuo Omaru
  • Method for improving the color of MTBE, ETBE and TAME
    Patent number: 5847224
    Abstract: A process for improving the color of oxygenates, such as MTBE, ETBE and TAME, which utilizes a hydrogenation treater in the presence of a catalyst, containing at least one noble metal, along with a circulation of hydrogen to remove the color. The process reduces existing color bodies in the oxygenate and may proceed at room temperature and at normal pressure for economically providing a completely clear product having a +30 saybolt number.
    Type: Grant
    Filed: June 23, 1995
    Date of Patent: December 8, 1998
    Assignee: Global Octanes Corporation
    Inventors: Kunio Koga, Misao Mori
  • Method for treating cancer patients
    Patent number: 5846928
    Abstract: A new immunotherapy to cancer patients is provided. In the therapy, lymphocytes collected from a patient by leukopheresis are treated with interferon-.alpha. in vitro for a short period of term and then returned to the patient intravenously. According to the therapy, reduction in sensitivity of tumor cells to natural killer-cell lysis due to administration of interferon-.alpha. is eliminated, the activities of NK cell and 2-5AS and interferon-producing capacity can be enhanced, a large amount of lymphocytes can be activated directly in vitro with the dose of optimally adjusted to the patient, none of side effects are found, and any other potentiators and comodulaators, which may not be allowed to use in vivo, can be added to the lymphocytes and removed therefrom before returning to the patient.
    Type: Grant
    Filed: August 1, 1996
    Date of Patent: December 8, 1998
    Assignee: PasKen Products Co., Ltd.
    Inventor: Tsunataro Kishida
  • Use of thrombolytic reagents for prevention of vascular disease
    Patent number: 5837688
    Abstract: The present invention relates to the administration of thrombolytic reagents such as tissue plasminogen activator (t-PA), streptokinase and/or urokinase, over prolonged periods of time for prevention of vascular disease such as cerebral vascular thrombosis, pulmonary embolism, deep venous thrombus, acute myocardial infarction and fresh or aged arterial thrombi. The invention relates generally to delivery systems that provide for sustained release of thrombolytic reagents such as tissue plasminogen activator (t-PA), streptokinase and/or urokinase, over prolonged periods of time. The thrombolytic reagents may be administered, for example, transdermally, topically, intranasally or orally.
    Type: Grant
    Filed: November 27, 1996
    Date of Patent: November 17, 1998
    Inventor: Mathew I. Gelfand
  • Method for the preparation of a medical solution
    Patent number: 5833949
    Abstract: A method for preparation of a medical solution from water and a plurality of concentrates, including at least one acid in gaseous form, comprises the steps of transporting the water from a source through a main conduit and successively adding the plurality of concentrates to the water in the main conduit at a plurality of predetermined points positioned along the main conduit.
    Type: Grant
    Filed: October 6, 1993
    Date of Patent: November 10, 1998
    Assignee: Gambro AB
    Inventors: Lennart Jonsson, Sven Jonsson
  • Method of treating insulin resistance
    Patent number: 5827856
    Abstract: The present invention provides a novel method for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation.
    Type: Grant
    Filed: April 2, 1996
    Date of Patent: October 27, 1998
    Assignee: Novo Nordisk A/S
    Inventors: Knud Erik Andersen, Rolf Hohlweg, Tine Krogh J.o slashed.rgensen, Peter Madsen, Henrik Sune Andersen, Uffe Bang Olsen, Polivka Zdenek, Silhankova Alexandra, Sidelar Karel
  • Pharmaceutical compositions containing famotidine and aluminum hydroxide or magnesium hydroxide
    Patent number: 5817340
    Abstract: A solid oral dosage form for the treatment of gastrointestinal disorders comprising a therapeutically effective amount of a therapeutically effective amount of guanidinothiazole compound; and a therapeutically effective amount of an antacid wherein the pharmaceutical and an antacid are separated by a barrier which is substantially impermeable to an antacid.
    Type: Grant
    Filed: November 25, 1996
    Date of Patent: October 6, 1998
    Assignee: McNeil-PPC, Inc.
    Inventors: Edward John Roche, Susan Decoteau, Eleanor Freeman
  • Fabric softening compositions with dye transfer inhibitors for improved fabric appearance
    Patent number: 5804219
    Abstract: The present invention relates to compositions and processes which incorporate water-soluble polymers, other than enzymes, containing .dbd.N--C(.dbd.O)-- (including PVP) and/or N-oxide groups into the wash, rinse, and/or drying cycle of a laundering process (e.g., via fabric softening compositions) for dye transfer inhibition in the subsequent wash cycle. Multiple wash cycles optimize the dye transfer inhibitor performance of these polymers, remove unwanted dye discoloration caused by dye transfer, and provide soil antiredeposition benefits.
    Type: Grant
    Filed: March 10, 1994
    Date of Patent: September 8, 1998
    Assignee: The Procter & Gamble Company
    Inventors: Toan Trinh, Stephanie Lin-Lin Sung, Helen Bernardo Tordil, Paul Arthur Wendland
  • N-?mercaptoacyl(amino acid or peptide)! compounds and S-lipophilic aliphatic carbonyl derivatives thereof as antihypertensives
    Patent number: 5801274
    Abstract: N-?Mercaptoacyl(amino acid or peptide)! compounds and S-lipophilic aliphatic carbonyl derivatives thereof, and pharmaceutical compositions comprising such compounds, as well as the use of these compounds as antihypertensives by the inhibition of neutral endopeptidase and/or peptidyldipeptidase A are disclosed. Methods for preparing such compounds and derivatives are disclosed also.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 1, 1998
    Assignee: Institut National de la Sante et de la Recherche Medicale
    Inventors: Marie-Claude Fournie-Zaluski, Bernard-Pierre Roques
  • Method of protecting brain tissue from cerebral infarction subsequent to ischemia
    Patent number: 5801160
    Abstract: Methods and pharmaceutical compositions for reducing the extent of infarction, particularly cerebral infarction subsequent to cerebral ischemia.
    Type: Grant
    Filed: March 18, 1997
    Date of Patent: September 1, 1998
    Assignee: Interneuron Pharmaceuticals, Inc.
    Inventors: Bobby Winston Sandage, Marc Fisher, Kenneth Walter Locke
  • Method for enhancing pregnancy success in an animal
    Patent number: 5792785
    Abstract: Enhancement of pregnancy success in an animal is achieved by a method of treatment which includes administration of a single dose of melatonin during follicular development. An additional dose of melatonin can be administered during pregnancy to modulate accessory follicle formation. Novel compositions, which include a mixture of melatonin isomers or analogs, are also useful for enhancing pregnancy success.
    Type: Grant
    Filed: November 24, 1995
    Date of Patent: August 11, 1998
    Assignee: Equitech Laboratories, Inc.
    Inventors: Dan Sharp, Brian D. Cleaver
  • Treatment of pruritus with vitamin D and analogs thereof
    Patent number: 5789399
    Abstract: A method for treating pruritus comprising topical administration of formulation of vitamin D or an analog of vitamin D is disclosed. The formulation comprises a therapeutically effective, water-based emulsion, water-based suspension or oil-based formulation of vitamin D or analog of vitamin D.
    Type: Grant
    Filed: October 2, 1996
    Date of Patent: August 4, 1998
    Inventor: Marilyn E. Strube
  • Method for treating alcohol dependence
    Patent number: 5783189
    Abstract: Isoflavonoids containing a carbon-carbon linked .beta.-D-glucose moiety at the C-8 position and isolated from the Chinese herbal plant Pueraria lobata are useful for treating alcohol dependence.
    Type: Grant
    Filed: April 23, 1996
    Date of Patent: July 21, 1998
    Assignee: Natural Pharmacia International, Inc.
    Inventors: Yue-Hu Pei, David Overstreet, Amir Hosein Rezvani, David Yue-Wei Lee
  • Co-production of perfluoromethyl perfluorovinyl ether and perfluoroethyl perfluorovinyl ether
    Patent number: 5777179
    Abstract: A process for the production of perfluoromethyl perfluorovinyl ether (PMVE) and perfluoroethyl perfluorovinyl ether (PEVE) from hexafluoropropylene epoxide (HFPO) and a mixture comprising carbonyl fluoride (CF) and perfluoroacetyl fluoride (PAF) is disclosed. The process includes a step (a) involving the reaction of hexafluoropropylene epoxide (HFPO) with a mixture of carbonyl fluoride (CF) and perfluoroacetyl fluoride (PAF) to produce a mixture of 2,3,3,3-tetrafluoro-2-(trifluoromethoxy)propionic acid fluoride (PMPF) and 2,3,3,3-tetrafluoro-2-(pentafluoroethoxy)propionic acid fluoride (PEPF). In a second step, a mixture of PMPF and PEPF made in the step (a) is dehalocarbonylated to produce a mixture of PMVE and PEVE.
    Type: Grant
    Filed: May 24, 1996
    Date of Patent: July 7, 1998
    Assignee: E. I. du Pont de Nemours and Company
    Inventors: Baishen Liang, Ming-Hong Hung, Paul Raphael Resnick
  • 2-acylaminopropanamides as growth hormone secretagogues
    Patent number: 5773441
    Abstract: This invention provides a series of novel substituted propanamides which are useful in the a physiological condition which may be modulated by an increase in growth hormone. This invention also provides methods for the treatment of such physiological conditions which comprise administering a growth hormone secretagogue as described in the present invention in combination with growth hormone releasing hormone.
    Type: Grant
    Filed: August 20, 1996
    Date of Patent: June 30, 1998
    Assignee: Eli Lilly and Company
    Inventors: Philip Arthur Hipskind, Jeffrey Alan Dodge
  • Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia
    Patent number: 5773434
    Abstract: Psychotic symptoms are treated by the administration of drugs which amplify the ability of natural stimulators of AMPA receptors to enhance the mediation of excitatory synaptic response. What is previously known about the activity and effectiveness of these drugs is unrelated to the etiology of psychotic symptoms. The invention finds particular utility in the treatment of schizophrenia.
    Type: Grant
    Filed: August 30, 1995
    Date of Patent: June 30, 1998
    Assignees: Gary A. Rogers, The Regents of the University of California
    Inventors: John Larson, Gary Lynch, Gary A. Rogers